<Page>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 8, 2002
Bio-Technology General Corp.
(Exact name of issuer as specified in its charter)
Delaware 0-15313 13-3033811
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
70 Wood Avenue South
Iselin, New Jersey 08830
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (732) 632-8800
None.
(Former address, if changed since last report.)
<Page>
ITEM 4. CHANGES IN REGISTRANT'S CERTIFYING ACCOUNTANT.
The Audit Committee of the Board of Directors of Bio-Technology General
Corp. (the "Company") annually considers and recommends to the Board the
selection of the Company's independent public accountants. As recommended by the
Company's Audit Committee, the Company's Board of Directors on May 8, 2002
decided to no longer engage Arthur Andersen LLP ("Arthur Andersen") as the
Company's independent public accountants and engaged KPMG LLP ("KPMG") to serve
as the Company's independent public accountants for 2002.
During the Company's two most recent fiscal years ended December 31,
2000 and 2001, and through the date of this Form 8-K, there were no
disagreements between the Company and Arthur Andersen on any matter of
accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements, if not resolved to Arthur Andersen's
satisfaction, would have caused Arthur Andersen to make reference to the subject
matter of the disagreement in connection with its reports. None of the
reportable events described under Item 304(a)(1)(v) of Regulation S-K occurred
within the Company's two most recent fiscal years ended December 31, 2000 and
2001 or through the date of this Form 8-K.
The audit reports of Arthur Andersen on the consolidated financial
statements of the Company as of and for the fiscal years ended December 31, 2000
and 2001 did not contain any adverse opinion or disclaimer of opinion, nor were
they qualified or modified as to uncertainty, audit scope or accounting
principles.
The Company provided Arthur Andersen with a copy of this Form 8-K.
Attached as Exhibit 16.1 to this Form 8-K is a copy of Arthur Andersen's letter,
dated May 8, 2002, stating its agreement with the statements concerning Arthur
Andersen.
During the Company's two most recent fiscal years ended December 31,
2000 and 2001, and through the date of this Form 8-K, neither the Company, nor
anyone acting on its behalf, consulted with KPMG with respect to the application
of accounting principles to a specified transaction, either completed or
proposed, or the type of audit opinion that might be rendered on the Company's
consolidated financial statements, or any other matters or events set forth in
Item 304(a)(2)(i) and (ii) of Regulation S-K. Although Arthur Andersen has
served as the Company's principal auditor, KPMG Somekh Chaikin has audited the
statutory financial statements of Bio-Technology General (Israel) Ltd., the
Company's wholly-owned Israeli subsidiary, for more than the last two fiscal
years.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(a) Financial Statements of Business Acquired.
None.
(b) Pro Forma Financial Information.
None.
(c) Exhibits.
16.1 Letter, dated May 8, 2002, from Arthur Andersen LLP
to the Securities and Exchange Commission.
<Page>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIO-TECHNOLOGY GENERAL CORP.
(Registrant)
By: /s/ John Bond
-----------------------------------
John Bond
Senior Vice President-Finance
Dated: May 15, 2002